Research Article
Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism
Table 1
Biochemical, hormonal, and densitometric parameters in patients and controls.
| | | Patients | Controls | | | | () | () |
| | Age (year) | 21.15 ± 1.96 | 21.70 ± 1.35 | 0.462 | | BMI (kg/m2) | 22.87 ± 4.06 | 21.50 ± 2.43 | 0.354 | | FSH (mIU/mL) | 1.30 ± 1.04 | 5.24 ± 2.64 | <0.001 | | LH (mIU/mL) | 0.81 ± 0.68 | 4.50 ± 2.10 | <0.001 | | TT (nmol/L) | 0.78 ± 0.42 | 19.80 ± 5.21 | <0.001 | | TC (mmol/L) | 4.71 ± 1.43 | 3.96 ± 0.50 | 0.146 | | TG (mmol/L) | 1.57 ± 1.13 | 0.88 ± 0.44 | 0.098 | | LDL-C (mmol/L) | 2.51 ± 0.94 | 2.22 ± 0.54 | 0.394 | | HDL-C (mmol/L) | 1.46 ± 0.35 | 1.44 ± 0.19 | 0.835 | | FBG (mmol/L) | 5.50 ± 0.52 | 5.49 ± 0.33 | 0.970 | | Insulin (μIU/mL) | 21.27 ± 7.68 | 7.95 ± 2.36 | 0.001 | | HOMA-IR | 5.31 ± 2.27 | 1.96 ± 0.66 | 0.002 | | 25(OH)-Vitamin D (ng/mL) | 15.49 ± 4.65 | 15.62 ± 5.52 | 0.955 | | SHBG (nmol/L) | 45.46 ± 14.00 | 22.30 ± 5.12 | <0.001 | | L2–4 (g/cm2) | 0.905 ± 0.153 | 1.191 ± 0.085 | <0.001 | | FN (g/cm2) | 0.802 ± 0.111 | 1.051 ± 0.055 | <0.001 | | TH (g/cm2) | 0.838 ± 0.123 | 1.116 ± 0.069 | <0.001 |
|
|
BMI: body mass index; FSH: follicle-stimulating hormone; LH: luteinizing hormone; T: testosterone; TC: total cholesterol; TG: total triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FBG: fasting blood glucose; HOMA-IR: homeostasis model assessment of insulin resistance; SHBG: sex hormone-binding globulin; L2–4: lumbar spine 2–4; FN: femoral neck; TH: total hip.
|
